2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-179155
    PI3K/mTOR-IN-19
    PI3K/mTOR-IN-19 is an orally active, potent, selective PI3K (IC50 = 4.23 nM) and mTOR (IC50 = 2.3 nM) inhibitor. PI3K/mTOR-IN-19 significantly inhibits Eca109 cell viability and induces apoptosis. PI3K/mTOR-IN-19 causes G0/G1 cell cycle arrest, decreased mitochondrial membrane potential, and demonstrates marked telomerase inhibitory activity. PI3K/mTOR-IN-19 modulates the expression of key apoptotic regulators (Bcl-2, Bax, and p53) and downregulates the PI3K/Akt/mTOR signaling pathway. PI3K/mTOR-IN-19 can be used for the study of esophageal cancer.
    PI3K/mTOR-IN-19
  • HY-179166
    PROTAC sEH-degrader-4
    PROTAC sEH-degrader-4 is a highly efficient PROTAC degrader that targets soluble epoxide hydrolase (sEH) (pDC50 = 10.3). PROTAC sEH-degrader-4 can be used for research on inflammation-related diseases. Pink: sEH ligand (HY-179169); Blue: E3 ligase CRBN ligand (HY-179168); Black: Linker.
    PROTAC sEH-degrader-4
  • HY-179168
    Thalidomide-C4-N2-C2-N3 2825005-43-2
    Thalidomide-C4-N2-C2-N3 is an E3 ligase ligand. Thalidomide-C4-N2-C2-N3 can bind to a target protein ligand with a linker to form a PROTAC molecule, PROTAC sEH-degrader-4 (HY-179166).
    Thalidomide-C4-N2-C2-N3
  • HY-179169
    sEH-H ligand 2 98%
    sEH-H ligand 2 is an sEH inhibitor and a ligand for the target protein for PROTAC (sEH). sEH-H ligand 2 can be used to synthesize PROTAC sEH-degrader-4 (HY-179166).
    sEH-H ligand 2
  • HY-179209
    TLR9-IN-2 2972638-16-5
    TLR9-IN-2 (Compound 20) is a selective inhibitor of Toll-like receptor 9 (TLR9) with IC50 values for TLR9, TLR7, and TLR8 of 25, 1400, and > 50,000 nM respectively. TLR9-IN-2 can be used for the study of fibrosis, autoimmune and inflammatory diseases.
    TLR9-IN-2
  • HY-179216
    KTT-1 2397562-26-2 98%
    KTT-1 is a kinetically selective and orally active HDAC2 inhibitor. KTT-1 exhibits high HDAC2-selectivity over HDAC1. KTT-1 inhibits osteoclast differentiation at an early stage by downregulating c-Fos expression. KTT-1 effectively suppresses arthritis symptoms in the collagen-induced arthritis (CIA) mouse model. KTT-1 can be used for the research of rheumatoid arthritis and neurodegenerative diseases.
    KTT-1
  • HY-179222
    Deoxy-thalidomide-OMe 1061605-49-9 98%
    Deoxy-thalidomide-OMe is an E3 ligase ligand. Deoxy-thalidomide-OMe can be used for synthesis of PROTAC LRRK2 Degrader-4 (HY-178796).
    Deoxy-thalidomide-OMe
  • HY-179246
    CXT29
    CXT29 is an orally active COX-2 inhibitor and a thromboxane A2 receptor (TP) antagonist. CXT29 exhibits COX inhibitory activity and selectivity, with IC50 values of 13 and 722 nM for COX-2 and COX-1 respectively. CXT29 inhibits platelet aggregation induced by U-46619 (HY-108566) (a TP agonist), with an IC50 of 96 nM. CXT29 effectively inhibits the production of TXB₂ and PGE₂, significantly reducing platelet aggregation and inflammatory pain in mice. CXT29 can be used for research on inflammatory pain and cardiovascular diseases.
    CXT29
  • HY-179274
    β2AR agonist 5 2759727-47-2
    β2AR agonist 5 (Compound alpha-β2-008) is a β2AR agonist, with an EC50 value of 0.19 nM. β2AR agonist 5 induces the BRET signal. β2AR agonist 5 can be used in the research of asthma and chronic obstructive pulmonary disease.
    β2AR agonist 5
  • HY-179292
    USP1-IN-14 3084277-96-0 98%
    USP1-IN-14 (compound 27) is a ubiquitin-specific protease 1 (USP1) inhibitor with an IC50 of 0.001 µM. USP1-IN-14 can be used for USP1-related cancers, autoimmune and inflammatory disorders research.
    USP1-IN-14
  • HY-179349
    PARP-1/2-IN-5 489457-75-2
    PARP-1/2-IN-5 (Compound 12) is a PARP-1/2 inhibitor, with the IC50 values for PARP-1 and PARP-2 being 118 and 11 nM respectively. PARP-1/2-IN-5 can be used for the study of inflammatory diseases and neurodegenerative disorders.
    PARP-1/2-IN-5
  • HY-179378
    XRF-1021 2968523-32-0 98%
    XRF-1021 is an orally active HIPK2 inhibitor (IC50 = 0.18 μM). XRF-1021 reduces the expression of fibrotic markers in TGF-β1 stimulated NRK-49F and HK-2 cells, including Fibronectin, Collagen I and α-SMA. XRF-1021 blocks TGF-β, NF-κB, p53, Wnt/β-catenin, and Notch signaling. XRF-1021 reduces renal injury and fibrosis in vivo. XRF-1021 can be used for the research of chronic kidney disease.
    XRF-1021
  • HY-179379
    EP4 receptor agonist 3 prodrug 98%
    EP4 receptor agonist 3 prodrug (Compound 9) is a prodrug of EP4 receptor agonist (Compound 1a). EP4 receptor agonist 3 prodrug itself has no agonistic activity on the EP4 receptor and needs to be specifically hydrolyzed by intestinal alkaline phosphatase (IAP) in the intestine to release the active molecule, which then exerts the EP4 receptor agonistic effect locally in the intestine. EP4 receptor agonist 3 prodrug has colonic targeting properties and significantly alleviates colitis in mice.
    EP4 receptor agonist 3 prodrug
  • HY-179394
    Immunoproteasome-IN-2 98%
    Immunoproteasome-IN-2 is selective immunoproteasome inhibitor with IC50 = 232.3 nM for LMP7, IC50 = 9384.9 nM for β5. Immunoproteasome-IN-2 exhibits ancillary inhibitory activity against LMP2 and MECL-1 subunits. Immunoproteasome-IN-2 demonstrates anti-inflammatory efficacy in a mouse model of arthritis and shows a favorable safety profile in toxicological studies with reduced hepatotoxicity and hematotoxicity. Immunoproteasome-IN-2 has LMP7/β5 selectivity directly correlated with lower systemic toxicity. Immunoproteasome-IN-2 can be employed for research in arthritis.
    Immunoproteasome-IN-2
  • HY-179407
    LT-104A 2574572-03-3
    LT-104A is a potent PDE4 inhibitor that elevates intracellular cAMP levels (EC50 = 1.9 μM) and inhibits PDE4D3 activity (IC50 = 9.3 μM). LT-104A activates the cAMP-PKA-CREB anti-inflammatory signaling pathway and suppresses NF-κB-related gene expression (Il1b and Nos2). LT-104A can be used for inflammation-related disease research.
    LT-104A
  • HY-179416
    CypD-IN-6
    CypD-IN-6 is a potent cyclophilin D (CypD/PPIF) inhibitor that inhibits CypD PPIase activity (Ki = 32 nM) and binds to CypD (Kd = 60 nM). CypD-IN-6 can be used for mitochondrial permeability transition pore (MPTP) related disease research such as ischemia-reperfusion injury and acute pancreatitis1.
    CypD-IN-6
  • HY-179417
    CypD-IN-7 98%
    CypD-IN-7 is a potent cyclophilin D (CypD/PPIF) inhibitor that inhibits CypD PPIase activity (Ki = 2.4 nM) and provides protection against mitochondrial permeability transition pore (MPTP) opening. CypD-IN-7 can be used for pancreatitis research.
    CypD-IN-7
  • HY-179422
    HDAC6-IN-68 98%
    HDAC6-IN-68 is an HDAC6 PROTAC ligand. HDAC6-IN-68 can be used to synthesize PROTAC HDAC6 degrader 7 (HY-179421).
    HDAC6-IN-68
  • HY-179423
    HDAC6 ligand-Linker Conjugate 3 98%
    HDAC6 ligand-Linker Conjugate 3 is a Target Protein Ligand-Linker Conjugate that incorporates a ligand for HDAC (HY-179422) and a PROTAC linker, which recruits E3 ligases. HDAC6 ligand-Linker Conjugate 3 can be used in the synthesis of PROTAC HDAC6 degrader 7 (HY-179421).
    HDAC6 ligand-Linker Conjugate 3
  • HY-179429
    NLRP3-IN-85 98%
    NLRP3-IN-85 (compound 5d) is a potent NLRP3 inhibitor that targets mitochondria in a ΔΨm-independent manner. NLRP3-IN-85 protects mitochondria from oxidative stress and inflammation damage and suppresses key inflammatory factors (NO, TNF-α, IL-6). NLRP3-IN-85 relives acute lung injury in mice and inhibits paw edema in rats. NLRP3-IN-85 can be used for acute lung injury (ALI) research.
    NLRP3-IN-85
Cat. No. Product Name / Synonyms Application Reactivity